Implementation and Uptake of Raltegravir Granules in Newborns Diagnosed With HIV Through Birth Testing in Maternity Settings in Zimbabwe During the COVID-19 Pandemic

Details

• Alternative Title:
  Pediatr Infect Dis J
• Personal Author:
  Denoeud-Ndam, Lise ; Stecker, Carl ; Andifasi, Precious ; Mushavi, Angela ; Maphosa, Talent ; Zondo, Mongiwa ; Murandu, Mildrate ; Gombakomba, Gladys ; Katirayi, Leila ; Mungati, More ; Bailey, Rebecca ; Weber, Rachel ; Rivadeneira, Emilia ; Hrapcak, Susan
• Description:
  Zimbabwe introduced raltegravir (RAL) granules at 14 facilities providing point-of-care HIV birth testing, aiming to initiate all newborns with HIV on a RAL-based regimen. From June 2020 to July 2021, we tested 3172 of the 6989 (45%) newborns exposed to HIV; we diagnosed 59(2%) with HIV infection, of whom 27 (46%) initiated RAL. The SARS-CoV-2 coronavirus disease pandemic exacerbated supply chain and trained provider shortages, contributing to low birth testing, RAL uptake and 6-month viral load testing.
• Subjects:
  Anti-HIV Agents COVID-19 Female HIV Infections Humans Infant, Newborn Pandemics Pregnancy Raltegravir Potassium SARS-CoV-2 Viral Load

  More +
• Source:
  Pediatr Infect Dis J. 42(7):573-575
• Pubmed ID:
  37000925
• Pubmed Central ID:
  PMC10289070
• Document Type:
  Journal Article
• Funding:
  NU2GGH001463/CC/CDC HHSUnited States/
• Place as Subject:
  Zimbabwe
• Volume:
  42
• Issue:
  7
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:dbbc307528a595ba2d9352ba9ce6eb5443f349e33da59b7000890afaa16de3fa
• Download URL:
  https://stacks.cdc.gov/view/cdc/130702/cdc_130702_DS1.pdf
• File Type:
  [PDF - 340.82 KB ]